Johnson & Johnson stock (US4781601046): ahead of next earnings, investors weigh healthcare giant’s resilience

Johnson & Johnson is approaching its next earnings release in mid?July while the stock trades near recent levels on the NYSE. We look at the latest profit trends, guidance signals and what matters now for US investors watching this diversified healthcare leader.

Johnson & Johnson is moving into a new earnings season with investor attention focused on how the healthcare group will navigate slowing growth in some segments and ongoing legal and regulatory risks. The company’s next quarterly report is scheduled for July 16, 2025, according to Zacks as of 07/03/2025. Ahead of that date, the stock has been trading relatively steadily on the New York Stock Exchange, as shown by recent price data from major US brokers such as Charles Schwab.

For the most recently reported quarter, Johnson & Johnson posted earnings of 2.77 USD per share, beating the Zacks Consensus Estimate of 2.57 USD per share and delivering a positive earnings surprise of 7.78%, according to Zacks as of 07/03/2025. The next report for the quarter ending in June 2025 is expected to show earnings of 2.64 USD per share, which would correspond to a year?over?year decline of about 6.38% based on the same source.

As of: 05/15/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Johnson & Johnson
• Sector/industry: Healthcare, pharmaceuticals, medical technology
• Headquarters/country: New Brunswick, New Jersey, United States
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: Innovative medicines, medical devices, consumer health products
• Home exchange/listing venue: New York Stock Exchange (ticker: JNJ)
• Trading currency: US dollar (USD)

Johnson & Johnson: core business model

Johnson & Johnson is one of the largest diversified healthcare companies in the world, with a history dating back more than a century. The group develops and markets prescription drugs, medical devices and consumer health products, serving hospitals, physicians and end consumers globally. Its scale and diversification are key elements of the business model and help smooth earnings across economic cycles.

In recent years, Johnson & Johnson has focused increasingly on its pharmaceutical and medical technology activities, which generally offer higher margins and stronger growth prospects than traditional consumer health. This strategic emphasis is reflected in capital allocation, research and development spending and portfolio management decisions. The move aligns the company with long?term trends such as an aging population, rising demand for advanced therapies and growing healthcare expenditures worldwide.

The company’s innovative medicines division develops treatments in areas such as oncology, immunology and neuroscience. Many of these products are protected by patents, which can support pricing power and profitability for a defined period. However, the business is also exposed to patent expirations and competition from generics and biosimilars once exclusivity ends. Managing this patent cycle is therefore central to Johnson & Johnson’s long?term strategy.

Alongside pharmaceuticals, Johnson & Johnson’s medical devices segment supplies implants, surgical tools and other equipment used in operating rooms and clinics. Demand in this area is influenced by procedure volumes, hospital budgets and broader healthcare utilization trends. During periods when elective procedures are postponed, device revenue can come under pressure, while recoveries in hospital activity often provide a tailwind.

Main revenue and product drivers for Johnson & Johnson

Revenue at Johnson & Johnson is driven primarily by a portfolio of leading pharmaceutical brands and a broad range of medical devices. Oncology and immunology therapies have been key contributors in recent years, reflecting industry?wide momentum in these therapeutic areas. New product launches and label expansions can support growth, while competition and pricing pressures may weigh on more mature products.

The medical devices business generates sales from orthopedics, surgery, cardiovascular and vision care products, among others. Procedure growth and innovation in minimally invasive techniques, robotics and digital integration are important themes here. When hospitals invest in new technology and patient volumes rise, Johnson & Johnson can benefit via increased demand for instruments, implants and related consumables.

Historically, consumer health products such as over?the?counter medicines and personal care brands also played a significant role. This portfolio has been reshaped through corporate actions and brand management to sharpen strategic focus and manage legal risks. Even though consumer health typically offers lower margins than innovative pharmaceuticals, it tends to be more resilient in downturns, which can be relevant for investors assessing earnings stability.

For US investors, Johnson & Johnson’s revenue mix has particular relevance because a substantial portion of sales is generated in the United States, one of the world’s largest and most profitable healthcare markets. Pricing dynamics in US pharmaceuticals, reimbursement policies and regulatory scrutiny can therefore have a material impact on the company’s overall performance.

Why Johnson & Johnson matters for US investors

Johnson & Johnson holds a prominent position in major US equity indices and is widely held by institutional and retail investors. Its large market capitalization and relatively stable dividend profile mean the stock often plays a role as a core holding in diversified portfolios. Earnings surprises, guidance updates and legal developments can therefore influence not only the share price but also broader healthcare and index performance.

Because Johnson & Johnson operates across multiple healthcare segments, its quarterly reports provide insights into trends affecting hospitals, physicians and patients in the US. Shifts in procedure volumes, drug pricing and reimbursement or demand for consumer health products can all signal changes in underlying economic conditions and policy developments. For investors, these signals are relevant when assessing other healthcare stocks as well.

The stock’s trading on the New York Stock Exchange in US dollars also simplifies access for domestic investors using US brokerages. Liquidity is typically high, allowing large orders to be executed with relatively modest price impact compared with smaller healthcare names. At the same time, the company’s global footprint introduces exposure to currency movements and international regulatory landscapes, which can add both opportunities and risks.

Conclusion

Johnson & Johnson enters its next earnings release with a recent track record of beating consensus expectations, but market observers also anticipate slower year?over?year growth for the upcoming quarter. The company’s diversified structure across pharmaceuticals, medical devices and consumer health can provide resilience, yet it also brings exposure to patent cycles, regulatory developments and litigation. For US investors, the stock remains an important reference point within the healthcare sector and broad equity benchmarks, and upcoming quarterly numbers and management commentary will be watched closely for signals on growth, margins and capital allocation without implying any specific investment recommendation.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.